Long acting interferon alpha 8 biobetter - UBI Pharma
Alternative Names: Long acting IFNα8 - UBI Pharma; UB-551Latest Information Update: 17 Jan 2024
At a glance
- Originator UBI Pharma
- Class Antineoplastics; Antivirals; Biobetters; Immunoglobulin Fc fragments; Immunotherapies; Interferons; Recombinant fusion proteins
- Mechanism of Action Interferon alpha replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Hepatitis B; Hepatitis C
Most Recent Events
- 20 Dec 2023 Preclinical trials in Cancer in Taiwan (Parenteral) (UBI Pharma pipeline, December 2023)
- 20 Dec 2023 Preclinical trials in Hepatitis B in Taiwan (Parenteral) (UBI Pharma pipeline, December 2023)
- 20 Dec 2023 Preclinical trials in Hepatitis C in Taiwan (Parenteral) (UBI Pharma pipeline, December 2023)